Literature DB >> 8688320

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.

P Kaaijk1, D Troost, O J de Boer, P Van Amstel, P J Bakker, S Leenstra, D A Bosch.   

Abstract

In the present study organotypic multicellular spheroids (OMS) were used to study the effects of chemotherapeutic agents on malignant gliomas. Compared with the frequently used cell line models, OMS have several advantages with respect to the preservation of the cellular heterogeneity and the structure of the original tumour. OMS prepared from seven glioma specimens were treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), daunorubicin or doxorubicin. After exposure to these drugs, the histology and cell proliferation of the OMS were analysed by immunohistochemistry and image analysis. Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. We found that OMS from gliomas are sensitive for daunorubicin and doxorubicin but not for BCNU in terms of tissue destruction and decrease in cell proliferation. In addition, all gliomas were P-gp and MRP negative, which is in accordance with the sensitivity for daunorubicin and doxorubicin. Considering the potential use of several new alternative drug delivery methods, such as intratumoural implantation of drug-impregnated polymers or liposomal encapsulation of cytostatic drugs, daunorubicin and doxorubicin might be effective in the treatment of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688320      PMCID: PMC2074578          DOI: 10.1038/bjc.1996.336

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

2.  Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.

Authors:  W K Yung; J R Shapiro; W R Shapiro
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

3.  Chemotherapeutic trials on human malignant astrocytomas in organ culture.

Authors:  R J Saez; R J Campbell; E R Laws
Journal:  J Neurosurg       Date:  1977-03       Impact factor: 5.115

Review 4.  In vitro drug sensitivity testing in human gliomas.

Authors:  D W Kimmel; J R Shapiro; W R Shapiro
Journal:  J Neurosurg       Date:  1987-02       Impact factor: 5.115

Review 5.  Chemotherapy for malignant gliomas.

Authors:  P L Kornblith; M Walker
Journal:  J Neurosurg       Date:  1988-01       Impact factor: 5.115

Review 6.  Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.

Authors:  M S Edwards; V A Levin; C B Wilson
Journal:  Cancer Treat Rep       Date:  1980

7.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

8.  Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.

Authors:  V A Levin; W Hoffman; R J Weinkam
Journal:  Cancer Treat Rep       Date:  1978-09

9.  Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.

Authors:  A M Deffie; T Alam; C Seneviratne; S W Beenken; J K Batra; T C Shea; W D Henner; G J Goldenberg
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

10.  Long-term culture of organotypic multicellular glioma spheroids: a good culture model for studying gliomas.

Authors:  P Kaaijk; D Troost; P K Das; S Leenstra; D A Bosch
Journal:  Neuropathol Appl Neurobiol       Date:  1995-10       Impact factor: 8.090

View more
  5 in total

1.  High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.

Authors:  K W Albrecht; P C de Witt Hamer; S Leenstra; P J Bakker; J H Beijnen; D Troost; P Kaaijk; A D Bosch
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

2.  Penetration of idarubicin into malignant brain tumor tissue.

Authors:  W Boogerd; I S Tjahja; M M van de Sandt; J H Beijnen
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

3.  Effects of radiation on a model of malignant glioma invasion.

Authors:  G S Bauman; W MacDonald; E Moore; D A Ramsey; B J Fisher; V R Amberger; R M Del Maestro
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.

Authors:  Ki-Up Kim; Shannon M Wilson; Keith S Abayasiriwardana; Rodney Collins; Lars Fjellbirkeland; Zhidong Xu; David M Jablons; Stephen L Nishimura; V Courtney Broaddus
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08-25       Impact factor: 6.914

5.  Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme.

Authors:  Majed Alghamdi; Filippo Chierchini; Dimitri Eigel; Christian Taplan; Thomas Miles; Dagmar Pette; Petra B Welzel; Carsten Werner; Wenxin Wang; Catia Neto; Mark Gumbleton; Ben Newland
Journal:  Nanoscale Adv       Date:  2020-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.